Lumos Pharma Stock Price on September 30, 2023
| LUMO Stock | USD 4.30 0.02 0.46% |
Below is the normalized historical share price chart for Lumos Pharma extending back to November 14, 2011. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Lumos Pharma stands at 4.30, as last reported on the 29th of November, with the highest price reaching 4.34 and the lowest price hitting 4.30 during the day.
If you're considering investing in Lumos Stock, it is important to understand the factors that can impact its price. Lumos Pharma appears to be somewhat reliable, given 3 months investment horizon. Lumos Pharma has Sharpe Ratio of 0.0587, which conveys that the firm had a 0.0587% return per unit of risk over the last 3 months. We have found thirty technical indicators for Lumos Pharma, which you can use to evaluate the volatility of the firm. Please exercise Lumos Pharma's Downside Deviation of 3.08, mean deviation of 2.35, and Risk Adjusted Performance of 0.054 to check out if our risk estimates are consistent with your expectations.
At this time, Lumos Pharma's Other Stockholder Equity is very stable compared to the past year. As of the 29th of November 2024, Capital Stock is likely to grow to about 143.5 K, while Total Stockholder Equity is likely to drop about 25.9 M. . At this time, Lumos Pharma's Price Book Value Ratio is very stable compared to the past year. As of the 29th of November 2024, Price To Book Ratio is likely to grow to 1.00, while Price To Sales Ratio is likely to drop 12.00. Lumos Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 11th of November 2011 | 200 Day MA 3.0249 | 50 Day MA 4.1048 | Beta 0.331 |
Lumos |
Sharpe Ratio = 0.0587
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | LUMO | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.38 actual daily | 30 70% of assets are more volatile |
Expected Return
| 0.2 actual daily | 3 97% of assets have higher returns |
Risk-Adjusted Return
| 0.06 actual daily | 4 96% of assets perform better |
Based on monthly moving average Lumos Pharma is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Lumos Pharma by adding it to a well-diversified portfolio.
Price Book 7.568 | Enterprise Value Ebitda 0.3853 | Price Sales 16.8658 | Shares Float 5.7 M | Wall Street Target Price 4.25 |
Related Headline
Pardes Biosciences Headline on 24th of July 2023
INVESTIGATION ACTION ALERT The Schall Law Firm Announces it ... by accesswire.com
LOS ANGELES, CA ACCESSWIRE July 24, 2023 The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Pardes Bioscience
Lumos Pharma Valuation on September 30, 2023
It is possible to determine the worth of Lumos Pharma on a given historical date. On September 30, 2023 Lumos was worth 3.57 at the beginning of the trading date compared to the closed value of 3.3. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Lumos Pharma stock. Still, in general, we apply an absolute valuation method to find Lumos Pharma's value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Lumos Pharma where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Lumos Pharma's related companies.
| Open | High | Low | Close | Volume | |
| 2.89 | 3.57 | 2.89 | 3.47 | 31,766 | |
09/29/2023 | 3.57 | 3.57 | 3.28 | 3.30 | 14,882 |
| 3.41 | 3.51 | 3.30 | 3.48 | 29,471 |
| Backtest Lumos Pharma | | | Lumos Pharma History | | | Lumos Pharma Valuation | Previous | Next |
Lumos Pharma Trading Date Momentum on September 30, 2023
| On October 02 2023 Lumos Pharma was traded for 3.48 at the closing time. The top price for the day was 3.51 and the lowest listed price was 3.30 . The trading volume for the day was 29.5 K. The trading history from October 2, 2023 was a factor to the next trading day price boost. The trading delta at closing time against the next closing price was 5.45% . The trading delta at closing time against the current closing price is 23.94% . |
Lumos Pharma Fundamentals Correlations and Trends
By evaluating Lumos Pharma's financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Lumos Pharma's main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Lumos financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Lumos Pharma Stock history
Lumos Pharma investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Lumos is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Lumos Pharma will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Lumos Pharma stock prices may prove useful in developing a viable investing in Lumos Pharma
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 8.1 M | 4.1 M | |
| Net Loss | -35.7 M | -37.5 M |
Lumos Pharma Quarterly Net Working Capital |
|
Lumos Pharma Stock Technical Analysis
Lumos Pharma technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
Lumos Pharma Period Price Range
Low | November 29, 2024
| High |
0.00 | 0.00 |
Lumos Pharma cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Lumos Pharma November 29, 2024 Market Strength
Market strength indicators help investors to evaluate how Lumos Pharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Lumos Pharma shares will generate the highest return on investment. By undertsting and applying Lumos Pharma stock market strength indicators, traders can identify Lumos Pharma entry and exit signals to maximize returns
Lumos Pharma Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Lumos Pharma's price direction in advance. Along with the technical and fundamental analysis of Lumos Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Lumos to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | 0.054 | |||
| Jensen Alpha | 0.2718 | |||
| Total Risk Alpha | (0.31) | |||
| Sortino Ratio | 0.0253 | |||
| Treynor Ratio | (0.28) |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lumos Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. To learn how to invest in Lumos Stock, please use our How to Invest in Lumos Pharma guide.You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lumos Pharma. If investors know Lumos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lumos Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.28) | Revenue Per Share 0.27 | Quarterly Revenue Growth 102.714 | Return On Assets (0.70) | Return On Equity (1.73) |
The market value of Lumos Pharma is measured differently than its book value, which is the value of Lumos that is recorded on the company's balance sheet. Investors also form their own opinion of Lumos Pharma's value that differs from its market value or its book value, called intrinsic value, which is Lumos Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lumos Pharma's market value can be influenced by many factors that don't directly affect Lumos Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lumos Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lumos Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lumos Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.